These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31505158)

  • 1. Performance-based pharmacy payment models: the case for change.
    Jackson J; Urick B
    Aust Health Rev; 2019 Oct; 43(5):502-507. PubMed ID: 31505158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Funding community pharmacy dispensing: A qualitative exploration of current and alternate models leading to the development of quality focused funding principles.
    Jackson J; Ruffini O; Livet M; Urick B
    Health Policy; 2022 Dec; 126(12):1263-1268. PubMed ID: 36220668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Framework for assessing pharmacy value.
    Urick BY; Urmie JM
    Res Social Adm Pharm; 2019 Nov; 15(11):1326-1337. PubMed ID: 30630670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration.
    Richard C; Urick BY; Pathak S; Jackson J; Livet M
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1568-1578. PubMed ID: 34714107
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic impact of increased clinical intervention rates in community pharmacy. A randomised trial of the effect of education and a professional allowance.
    Benrimoj SI; Langford JH; Berry G; Collins D; Lauchlan R; Stewart K; Aristides M; Dobson M
    Pharmacoeconomics; 2000 Nov; 18(5):459-68. PubMed ID: 11151399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and effect of performance-based pharmacy payment models.
    Urick BY; Pathak S; Hughes TD; Ferreri SP
    J Manag Care Spec Pharm; 2021 Mar; 27(3):306-315. PubMed ID: 33645246
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact on community pharmacy of the changing generic medicine substitution landscape.
    Hattingh HL; Maganlal S; King MA
    J Law Med; 2010 May; 17(5):761-71. PubMed ID: 20552939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forging a novel provider and payer partnership in Wisconsin to compensate pharmacists for quality-driven pharmacy and medication therapy management services.
    Trapskin K; Johnson C; Cory P; Sorum S; Decker C
    J Am Pharm Assoc (2003); 2009; 49(5):642-51. PubMed ID: 19748873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paying for quality not quantity: a wisconsin health maintenance organization proposes an incentive model for reimbursement of chiropractic services.
    Pursel KJ; Jacobson M; Stephenson K
    J Manipulative Physiol Ther; 2012 Jul; 35(6):472-6. PubMed ID: 22926019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of financial incentives on the quality of health care provided by primary care physicians.
    Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discounting of medicines in Australian community pharmacies.
    Thai LP; Vitry AI; Moss JR
    Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Service provision in the wake of a new funding model for community pharmacy.
    Smith AJ; Scahill SL; Harrison J; Carroll T; Medlicott NJ
    BMC Health Serv Res; 2018 May; 18(1):307. PubMed ID: 29716610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for community-based medication management services in value-based health plans.
    Smith MA; Spiggle S; McConnell B
    Res Social Adm Pharm; 2017; 13(1):48-62. PubMed ID: 26904962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Providing patient care in community pharmacies in Australia.
    Benrimoj SI; Roberts AS
    Ann Pharmacother; 2005 Nov; 39(11):1911-7. PubMed ID: 16219897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year financial analysis of pharmacy services at an independent community pharmacy.
    Doucette WR; McDonough RP; Mormann MM; Vaschevici R; Urmie JM; Patterson BJ
    J Am Pharm Assoc (2003); 2012; 52(2):181-7. PubMed ID: 22370381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A national survey exploring oral healthcare service provision across Australian community pharmacies.
    Freeman CR; Abdullah N; Ford PJ; Taing MW
    BMJ Open; 2017 Sep; 7(9):e017940. PubMed ID: 28963314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical care in community pharmacies: practice and research in the US.
    Christensen DB; Farris KB
    Ann Pharmacother; 2006; 40(7-8):1400-6. PubMed ID: 16868221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan.
    Lee YC; Huang KH; Huang YT
    Health Policy Plan; 2007 Nov; 22(6):427-35. PubMed ID: 17901065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.